Fritextsökning
Artiklar per år
Innehållstyper
-
Young, bright and committed to labtech
Ghazal Voghoui recently bought her first apartment and finally settled in Stockholm again. Last year, she finished her law studies and she is relieved to be back after living in Geneva for four years. On November 10 she will take a big career leap, becoming the new CEO of Swedish Labtech.
-
From planning stage to handshake
"Partnering is an effective tool to get in touch with the decision makers high up in an organization's administration," says Camilla Huse Bondeson at Conlega. And according to her, rigorous planning is the way to succeed.
-
The winner of the race
She learned how to work hard at an early age and her devotion has certainly paid off. Whether it is field running or running a company, the key to success is focus according to Yvonne Mårtensson.
-
With their hands on the legal levers
It is wonderful news for the Scandinavian scientific community. At the end of May it stood clear that Lund will host to the European Spallation Source.
-
Absorber säljer till USA
Två ledande amerikanska transplantationskliniker köper bolagets antikroppstest.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.
-
Re-painting the big pig-ture
Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Grant for development projects in Gothenburg
Seven research projects receive SEK 1 million to promote commercialization of early drug development and medical technology.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
-
New study of toxins and heart disease
Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study will try to evaluate this, and one thousand people are to be included.
-
EUR 2 million for peanut allergies
ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.
-
Biovitrum sells UK part
Biovitrum will soon spin-out a British subsidary
-
EU says yes to Roche drug
EU approves a first in class therapy for treatment of patients with moderate to severe form of rheumatoid arthritis.
-
Finnish-Dutch engineering cooperation continues
The University of Helsinki and ASM International renew a fice year research agreement on Atomic Layer Deposition.
-
Respiratorius hunts millions
The biopharmaceutical company Respiratorius has got a new CEO, who starts a public new share issue to catch almost SEK ten million.
-
Biotech goes white and bright
White biotech could become Denmark's next blossoming business area.
-
Oasmia gets a confirmation
FDA has granted Oasmia an expedited review status for Paclical Vet.
-
New NO product reduces diabetic pain
The Swedish medtech company Nolabs has announced that it has achieved an important milestone in the development of a new line of products.
-
Woman deficit in Swedish research
The IP firm Awapatent will soon launch its Innovation Barometer 2009. This year Awapatent reveals that the statistics is even worse, compared to last year.
-
Abbott expands by acquisition
An acquisition gives Abbott a leadership position in another large and growing medical device segment.